Leading global health institutions digitize pathology workflows with Philips to enhance disease diagnoses
Pathologists across Singapore, Austria, Germany, Belgium and the UK adopt Philips Digital Pathology Solutions to drive cutting-edge diagnostics
EINDHOVEN, Netherlands, Sept. 8, 2015 /PRNewswire/ -- As the number of trained pathologists decreases while the aging population and complexity of cancer is on the rise, Royal Philips (NYSE: PHG, AEX: PHIA) today announced the growing adoption of its Digital Pathology Solutions by health systems across the globe who are enhancing their operations. Through its IntelliSite Pathology Solution*, Philips enables health care organizations to reinvent the traditional histopathology workflow, enhance efficiency and productivity, and improve the confidence in making diagnosis.
Photo - http://photos.prnewswire.com/prnh/20150908/264234
Photo - http://photos.prnewswire.com/prnh/20150908/264235
Through examination of patient tissue samples, pathology plays a crucial role in the diagnosis, management and prevention of a variety of diseases, including cancer. As health care cost and quality pressures continue to mount, digital pathology can help improve the efficiency and quality of cancer diagnostics. Several high-volume and networked pathology institutions across the world have implemented the Philips digital pathology platform, which offers an integrated approach to improve workflows, enhance collaboration capabilities to speed up consults, unify patient data and enable a flexible growth path to get more information from tumor tissue.
"Modern pathology labs are coming under continued pressure to increase throughput and efficiency while improving quality," said Russell Granzow, General Manager of Philips Digital Pathology Solutions. "As the shift towards personalized medicine requires pathology data that guides the right therapy for the right patient at the right time, Philips is driving the evolution toward digitized workflows to ensure pathologists are empowered to meet industry demand."
- Supporting Archiving in Singapore
Singapore General Hospital (SGH), the flagship hospital of the country's public health care system, recently implemented the world's largest digital pathology installation in its diagnostic laboratory. To handle its more than 50,000 pathology cases a year, SGH will leverage more than 1.6 petabytes of disk storage and 1.6 petabytes of tape archiving storage to avoid the challenges of storing glass tissue slides – like loss, breakage, degrading or manual archiving errors – and reduce the physical space needed to manage all of these records.
- Full Scale Installation in Belgium
The AZ Sint Jan in Brugge, Belgium completed a full-scale installation that is designed to accommodate full digital histopathology diagnosis. Recognizing that a short transitional process to digital would save a great deal in efficiency and costs, the lead pathologist Dr. Van den Berghe opted to avoid a gradual transitioning strategy by coordinating a full digital implementation to benefit from this new way of working.
- Providing Remote Diagnostic Services across Austria
In Austria two private pathology laboratories in Hall in Tirol and St. Pölten provide diagnostic services for hospitals and private medical centers across Austria. To speed up sample diagnosis and to implement interactive consultation of experts for the patients, Dr. Soleiman is creating an international network of pathologists by transitioning to an entirely digital workflow with about 200,000 histology slides per year with the Philips IntelliSite solution.
- Germany's Largest Telemedicine Platform Goes Online
The "CCS Telehealth Ostsachsen" platform is provided by a subsidiary of Dresden's university clinic and T-Systems International. The European pilot scheme offers a broad range of possibilities in networked medical care and is intended to overcome former limitations. Incorporating digital pathology, pathologists have the opportunity to analyze digitally captured tissue samples and to digitally consult a council of other specialists with the aim to improve patient diagnosis.
- Expanding Teams through Virtualization in the UK
Sheffield Teaching Hospitals (STH) NHS Foundation Trust will partner with Hull and East Yorkshire Hospitals NHS Trust to develop a service for remote digital reporting of pathology cases. By addressing the long standing problem of a shortage of histopathologists in the United Kingdom, this unique collaboration for the UK enables the partners to offer their service to other hospitals in the Yorkshire and Humber region and beyond, and facilitates access to subspecialised diagnostic histopathology service for all patients. The system is designed to scale should more sites and pathology laboratories join this collaboration.
Across the globe, leading institutions are leveraging Philips' experience in clinical digital transformation to help pathology laboratories make that next step in workflow improvement and accelerate knowledge sharing between care providers.
For further information, please contact:
Hans Driessen
Philips Digital Pathology Solutions
+31 6 10 610 417
hans.driessen@philips.com
Steve Klink
Philips Group Communications
+31 6 1088 8824
steve.klink@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
* Philips IntelliSite Pathology Solution is CE marked for primary diagnostics in the EU and Health Canada. In the U.S., Philips IntelliSite Pathology Solution is cleared by FDA for diagnostic use in the evaluation of HER2 expression in breast cancer and is offered for research use (RUO).
Share this article